BMS
TMB-High Status Does Not Predict Opdivo-Yervoy Response in Pan-Tumor Analysis
In a retrospective analysis, tumor mutational burden was not associated with improved responses to combination immunotherapy, researchers found.
Purple Biotech, BMS Dose First Patient in Clinical Trial of CM24-Opdivo Combo
The companies plan to conduct a biomarker analysis as part of the Phase Ib/II clinical trial evaluating the anti-CEACAM1 agent plus immunotherapy for patients with advanced solid tumors.
AACR Study Tests Immunogenic Signature in Prostate Cancer Patients on Dual Checkpoint Inhibitor
Although the trial didn't hit its prespecified response target to Opdivo and Yervoy, researchers will further study the promising signals they saw in biomarker groups.
The autologous, anti-BCMA CAR T-cell therapy may be the first to garner FDA approval for multiple myeloma patients but competing products may soon catch up.
FDA Approves Bristol Myers Squibb, Bluebird Bio's Multiple Myeloma CAR T-Cell Therapy Abecma
The FDA based its approval on the KarMMa trial, in which 72 percent of evaluable multiple myeloma patients responded to the autologous, anti-BCMA therapy.